| 001 | 124441 | ||
| 005 | 20240228145514.0 | ||
| 024 | 7 | _ | |a 10.1007/s10549-017-4261-1 |2 doi |
| 024 | 7 | _ | |a pmid:28439738 |2 pmid |
| 024 | 7 | _ | |a 0167-6806 |2 ISSN |
| 024 | 7 | _ | |a 1573-7217 |2 ISSN |
| 024 | 7 | _ | |a altmetric:19582191 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-01318 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a von Hagens, Cornelia |0 0000-0001-8259-4946 |b 0 |
| 245 | _ | _ | |a Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2). |
| 260 | _ | _ | |a Dordrecht [u.a.] |c 2017 |b Springer Science + Business Media B.V. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1511258656_9877 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The antimalarial drug artesunate (ART) is a promising candidate for cancer treatment as it displays anticancer effects in various models. While in short-term treatment of malaria, an excellent safety profile has been found for ART, the potential long-term treatment of cancer patients demands a phase I dose-finding clinical trial determining the daily ART dose which would be well tolerated as add-on therapy.Patients with metastatic breast cancer were to receive either 100 or 150 or 200 mg oral ART daily as add-on to their guideline-based oncological therapy for a study period of four weeks with frequent clinical and laboratory monitoring until 4-8 weeks thereafter. According to the statistical design, recruitment was scheduled in groups of three patients in order not to miss a more than 33% frequency of dose-limiting adverse events (DL-AE) prior to dose escalation.Twenty-three patients were recruited, and all planned dose levels were applied. During the actual trial period of 4 ± 1 weeks, three patients experienced six DL-AEs altogether (leucopenia, neutropenia, asthenia, anemia) possibly related to ART (not exceeding 33% in any dose level).Up to 200 mg/d (2.2-3.9 mg/kg/d) oral ART were safe and well tolerated; therefore, 200 mg/d are recommended for phase II/III trials. Safety monitoring should include reticulocytes, NTproBNP, as well as audiological and neurological exploration. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Walter-Sack, Ingeborg |b 1 |
| 700 | 1 | _ | |a Goeckenjan, Maren |b 2 |
| 700 | 1 | _ | |a Osburg, Julia |b 3 |
| 700 | 1 | _ | |a Storch-Hagenlocher, Brigitte |b 4 |
| 700 | 1 | _ | |a Sertel, Serkan |b 5 |
| 700 | 1 | _ | |a Elsässer, Michael |b 6 |
| 700 | 1 | _ | |a Remppis, Bjoern Andrew |b 7 |
| 700 | 1 | _ | |a Edler, Lutz |0 P:(DE-He78)621efe295db6fdfa7f9f95011a5ea943 |b 8 |u dkfz |
| 700 | 1 | _ | |a Munzinger, Judith |b 9 |
| 700 | 1 | _ | |a Efferth, Thomas |b 10 |
| 700 | 1 | _ | |a Schneeweiss, Andreas |b 11 |
| 700 | 1 | _ | |a Strowitzki, Thomas |b 12 |
| 773 | _ | _ | |a 10.1007/s10549-017-4261-1 |g Vol. 164, no. 2, p. 359 - 369 |0 PERI:(DE-600)2004077-5 |n 2 |p 359 - 369 |t Breast cancer research and treatment |v 164 |y 2017 |x 1573-7217 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:124441 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)621efe295db6fdfa7f9f95011a5ea943 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |2 G:(DE-HGF)POF3-300 |v Cancer risk factors and prevention |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2017 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BREAST CANCER RES TR : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::